Analysis of the side effects and efficacy of Vidicitomab (Aidexi)

Disitamab (Disitamab) is an innovative humanized antibody-drug conjugate (Antibody-Drug Conjugate, ADC), mainly targets HER2 (human epidermal growth factor receptor 2) positive tumors, such as advanced gastric cancer, breast cancer and some urothelial cancer patients. It uses antibodies to specifically bind to the HER2 receptor on the surface of tumor cells and accurately deliver cytotoxic drugs to the tumor site, thereby exerting an anti-cancer effect. This design can minimize damage to normal tissue and improve treatment specificity and drug utilization efficiency. Disitamab has shown high clinical efficacy, but also has certain side effects, which requires scientific monitoring and management during use.

The main effect of vedicitomab is to precisely killHER2 positive tumor cells. The drug is endocytosed after binding to the HER2 receptor on the surface of the tumor cell. The coupled small molecule cytotoxic drug is released within the tumor cell, destroying the DNA or microtubule structure of the tumor cell, thereby leading to tumor cell apoptosis. Clinical trial data show that Disitamab can significantly prolong the progression-free survival (PFS) of patients with HER2-positive advanced gastric cancer or breast cancer, and induce tumor shrinkage in some patients. In addition, it has also shown certain efficacy in patients with tumors with low HER2 expression, providing a new treatment option for people who cannot be covered by traditional HER2 targeted drugs. Compared with traditional chemotherapy, Disitamab has the advantages of strong targeting and relatively small damage to normal tissues, and can improve patients' quality of life.

However, some side effects may occur during use of vedicitumab. Common adverse reactions include nausea, vomiting, diarrhea, fatigue, decreased platelets or white blood cells, and injection site reactions. Some patients may experience liver function abnormalities, such as elevated serum aminotransferases, or an increased risk of cardiotoxicity. Therefore, regular monitoring of liver and kidney function and hematological indicators is required during medication. In rare cases, serious adverse events may occur, such as lung infection or allergic reactions, requiring immediate discontinuation and management. For high-risk patients or elderly patients, physicians usually adjust the dose or dosing interval based on the patient's specific condition to balance efficacy and safety.

In clinical applications,DisitamabIt is not only suitable for single-agent treatment, but can also be used in combination with other chemotherapy or immunotherapy to improve the therapeutic effect. Its administration method is usually intravenous infusion, once every two to three weeks, and the dose needs to be individually adjusted based on the patient's body surface area and condition. During the long-term treatment process, patients need to pay close attention to their own reactions and seek medical treatment promptly when obvious discomfort occurs. At the same time, doctors should evaluate the efficacy and toxicity based on imaging and laboratory test results, and dynamically adjust treatment plans. In summary, vedicitomab has shown high efficacy and good safety in the treatment of HER2-positive tumors, but side effects still need to be taken seriously, and scientific management and monitoring are the key to ensuring patient benefit.